Welcome back,

CONFERENCE UPDATE

ASCO 2024

The 2024 American Society Of Clinical Oncology (Asco) Annual Meeting

May 31-Jun 4, 2024 |

Chicago, United States

2024

Phase 3 PhALLON trial reveals high rates of MRD negativity at any time and prolonged PFS with ponatinib in patients with newly diagnosed Ph+ ALL

HEMATOLOGY
|
ONCOLOGY

12 Sep 2024
First-line lorlatinib continues to show PFS benefit over crizotinib in patients with advanced ALK+ NSCLC: 5-year follow-up of the CROWN study
RESPIROLOGY

12 Sep 2024
Local long-term study reveals high chronic health and mortality risks for nasopharyngeal cancer survivors
ONCOLOGY

12 Sep 2024
Observational study highlights clinical characteristics and treatment patterns of patients with high-risk prostate cancer in Asia-Pacific

ONCOLOGY
|
UROLOGY

26 Aug 2024
Improved outcomes with FLOT perioperative chemotherapy vs. CROSS neoadjuvant chemoradiation for esophageal cancer: The ESOPEC Trial
GASTROENTEROLOGY & HEPATOLOGY

6 Aug 2024
Liver transplantation + chemotherapy improves survival rates for patients with unresectable colorectal liver metastases

ONCOLOGY
|
GASTROENTEROLOGY & HEPATOLOGY

26 Jul 2024
EFS improvements for early-stage TNBC patients with carboplatin addition to standard therapy

OBSTETRICS & GYNECOLOGY
|
ONCOLOGY

23 Jul 2024

eaa0190a-4510-467f-900f-c94c7b668484